Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05707377 · ClinicalTrials.gov registry record · Phase 2
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
A Phase 2 study of Primary Membranous Nephropathy, sponsored by BeOne Medicines.
- Active
- Registry status
- Phase 2
- Development phase
- 178
- Enrollment target
- 20
- Study locations
NCT05707377 is a Phase 2 study of Primary Membranous Nephropathy that is active but no longer recruiting, run by BeOne Medicines. The registered enrollment target is 178 participants, above the 114-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (56% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT05707377, a Phase 2 study of Primary Membranous Nephropathy, is active but no longer recruiting, sponsored by BeOne Medicines.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 178 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy (PMN) who are on optimal supportive care.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Tacrolimus
Study Locations (20)
Fujian
- Fujian Medical University Union Hospital - Fuzhou
- The First Affiliated Hospital of Fujian Medical University - Fuzhou
- The First Affiliated Hospital of Xiamen University - Xiamen
Guangdong
- Guangdong Provincial Peoples Hospital - Guangzhou
- The First Affiliated Hospital, Sun Yat Sen University - Guangzhou
- Peking University Shenzhen Hospital - Shenzhen
California
- Amicis Research Center - Northridge
- Stanford University - Palo Alto
Other
- Instituto Pro Renal Brasil - Curitiba
- Hcfmusp Hospital Das Clinicas Da Faculdade de Medicina Da Universidade de Sao Paulo - São Paulo
Beijing Municipality
- Beijing An Zhen Hospital, Capital Medical University - Beijing
- Peking University First Hospital - Beijing
Minnesota
- Intermed Consultants - Minneapolis
Nevada
- Kidney Specialist of Southern Nevada (Ksosn) - Las Vegas
Ohio
- University of Cincinnati College of Medicine - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2023-04-17 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05707377
The ClinicalTrials.gov registry entry for NCT05707377 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 114-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (56% higher). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Membranous Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Zanubrutinib is the first listed.
NCT05707377 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Fujian, Guangdong, California.
Frequently Asked Questions
What is clinical trial NCT05707377 about?
NCT05707377 is a clinical study titled "A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy". The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropat...
What is the current status of trial NCT05707377?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2023-04-17. Estimated completion is 2027-10.
What conditions does trial NCT05707377 study?
This clinical trial studies the following conditions: Primary Membranous Nephropathy.
What interventions are being tested in trial NCT05707377?
The interventions under investigation include: Zanubrutinib (DRUG), Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT05707377?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05707377 being conducted?
This trial has 20 study locations across California, Minnesota, Nevada, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Membranous Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of WAL0921 in Patients With Glomerular Kidney Diseases
RECRUITING · Phase 2
-
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
RECRUITING · Phase 2
-
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
RECRUITING · Phase 2
-
A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
RECRUITING · Phase 2
-
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
RECRUITING · Phase 3
-
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.